Illumina, Inc. $ILMN Shares Newly Bought by Private Wealth Asset Management LLC

Private Wealth Asset Management LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,094 shares of the life sciences company’s stock, valued at approximately $1,668,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Private Advisor Group LLC purchased a new position in shares of Illumina in the 3rd quarter worth about $510,000. Focus Advisor Solutions LLC grew its position in Illumina by 68.8% during the 3rd quarter. Focus Advisor Solutions LLC now owns 25,224 shares of the life sciences company’s stock worth $6,904,000 after acquiring an additional 10,278 shares during the last quarter. Independent Advisor Alliance purchased a new position in Illumina in the 3rd quarter worth approximately $689,000. OneAscent Financial Services LLC bought a new stake in Illumina during the 3rd quarter valued at $5,128,000. Finally, Stephens Investment Management Group LLC raised its stake in shares of Illumina by 9.3% during the third quarter. Stephens Investment Management Group LLC now owns 587,929 shares of the life sciences company’s stock valued at $160,904,000 after acquiring an additional 50,003 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Trading Down 3.9%

NASDAQ:ILMN opened at $192.82 on Friday. The stock has a market cap of $29.15 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 2.69 and a beta of 1.46. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average price is $248.27 and its 200-day moving average price is $181.05. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. During the same period in the previous year, the business earned $1.34 EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on ILMN shares. JPMorgan Chase & Co. dropped their price target on Illumina from $320.00 to $300.00 and set an “overweight” rating for the company in a research note on Friday, October 30th. Deutsche Bank lowered shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. Citigroup boosted their target price on Illumina from $113.00 to $210.00 and gave the stock a “sell” rating in a report on Monday, November 2nd. Stephens cut Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 target price on the stock. in a research note on Friday, October 23rd. Finally, Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Nine investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $243.72.

View Our Latest Stock Report on ILMN

More Illumina News

Investors following ILMN have been watching these news items:

  • Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result highlights the company’s data and AI capabilities, although the financial impact is not yet clear. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
  • Neutral Sentiment: Bernstein reportedly maintained a Hold rating, suggesting a cautious stance rather than a new positive catalyst. Illumina Gets a Hold from Bernstein
  • Negative Sentiment: Voluntary Class II recalls linked to cybersecurity vulnerabilities in several diagnostic sequencing instruments have heightened concerns about operational risk and data integrity. The report also notes recent weakness in the shares, adding to near-term pressure. Is Illumina Undervalued Following Its Cybersecurity Recalls?

Insiders Place Their Bets

In related news, Director Keith Meister sold 231,433 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $238.52, for a total value of $55,201,399.16. Following the sale, the director owned 538,917 shares in the company, valued at approximately $128,542,482.84. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 1,201,292 shares of company stock worth $270,151,290 in the last 90 days. 2.90% of the stock is owned by corporate insiders.

Illumina Profile

(Free Report)

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.